Evidence map›Paper›PMID 23667685›Full record

ArticlePloS one2013

Analysis of URI nuclear interaction with RPB5 and components of the R2TP/prefoldin-like complex.

Paolo Mita, Jeffrey N Savas, Susan Ha, Nabil Djouder, John R Yates, Susan K Logan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Multifaceted role ofMedComm · 2024
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. R2TP/PAQosome as a promising chemotherapeutic target in cancer.The Japanese dental science review · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Paolo MitaDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America.
Jeffrey N Savas
Susan Ha
Nabil Djouder
John R Yates
Susan K Logan
New York University · USScripps Research Institute · USSpanish National Cancer Research Centre · ES

Funding

TrainingP41GM103533 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2012 to 2021
$20.7M
Quantitative Proteome Analysis of Brain DevelopmentR01MH067880 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI YATES III, JOHN R · 2003 to 2017
$7.1M
Transcription repression in prostate cancerR01CA112226 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOGAN, SUSAN K. · 2008 to 2019
$4.2M
Mechanism of ART-27 Function in Prostate CancerF31CA113285 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NWACHKWU, JEROME C · 2004 to 2008
$166k
Quantitative Proteomic Approach to Identify the Mechanism of Alzheimer's DiseaseF32AG039127 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI SAVAS, JEFFREY NICHOLAS · 2011 to 2014
$117k
NCI NIH HHS F31 CA113285NCI NIH HHS R01 CA112226NIA NIH HHS F32 AG039127NIA NIH HHS F32AG039127NIGMS NIH HHS P41 GM103533NIMH NIH HHS R01 MH067880
6 · The paper itself

Abstract

Unconventional prefoldin RPB5 Interactor (URI) was identified as a transcriptional repressor that binds RNA polymerase II (pol II) through interaction with the RPB5/POLR2E subunit. Despite the fact that many other proteins involved in transcription regulation have been shown to interact with URI, its nuclear function still remains elusive. Previous mass spectrometry analyses reported that URI is part of a novel protein complex called R2TP/prefoldin-like complex responsible for the cytoplasmic assembly of RNA polymerase II. We performed a mass spectrometry (MS)-based proteomic analysis to identify nuclear proteins interacting with URI in prostate cells. We identified all the components of the R2TP/prefoldin-like complex as nuclear URI interactors and we showed that URI binds and regulates RPB5 protein stability and transcription. Moreover, we validated the interaction of URI to the P53 and DNA damage-Regulated Gene 1 (PDRG1) and show that PDRG1 protein is also stabilized by URI binding. We present data demonstrating that URI nuclear/cytoplasmic shuttling is affected by compounds that stall pol II on the DNA (α-amanitin and actinomycin-D) and by leptomycin B, an inhibitor of the CRM1 exportin that mediates the nuclear export of pol II subunits. These data suggest that URI, and probably the entire R2TP/prefoldin-like complex is exported from the nucleus through CRM1. Finally we identified putative URI sites of phosphorylation and acetylation and confirmed URI sites of post-transcriptional modification identified in previous large-scale analyses the importance of which is largely unknown. However URI post-transcriptional modification was shown to be essential for URI function and therefore characterization of novel sites of URI modification will be important to the understanding of URI function.

Indexed as

Active Transport, Cell NucleusBlotting, WesternCell Line, TumorCell NucleusDNA-Binding ProteinsDNA-Directed RNA PolymerasesDNA PrimersExportin 1 ProteinFatty Acids, UnsaturatedGene Expression RegulationHumansImmunoprecipitationIntracellular Signaling Peptides and ProteinsKaryopherinsLuciferasesMaleDNA-Binding ProteinsDNA-Directed RNA PolymerasesDNA PrimersExportin 1 ProteinFatty Acids, UnsaturatedIntracellular Signaling Peptides and ProteinsKaryopherinsleptomycin BLuciferasesMultiprotein ComplexesPDRG1 protein, humanPOLR2E protein, humanReceptors, Cytoplasmic and NuclearRepressor ProteinsRNA Polymerase IIRNA, Small InterferingURI1 protein, human

Identifiers

PMID23667685
PMCPMC3648552
OpenAlexW2035982512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.